Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
U6 small nuclear RNA 9 (RNU6-9) encodes a variant of U6 snRNA, a non-coding RNA critical for the function of the spliceosome—the molecular machine responsible for removing introns from precursor messenger RNA in eukaryotic cells[5][1][3]. U6 snRNA is highly conserved and present in multiple gene copies in vertebrates; RNU6-9 is one such copy[1]. U6 snRNA, together with U1, U2, U4, and U5 snRNAs, and numerous proteins, forms small nuclear ribonucleoproteins (snRNPs) that catalyze the two transesterification steps of splicing[5]. U6 snRNA directly participates at the catalytic core of the spliceosome, binding with other snRNAs and proteins, and base pairing to intron splice sites[5][1]. While dysregulation of U6 snRNA has been observed in disease models, particularly infectious or cancerous states, it is not a classical drug target nor is its modulation currently used clinically[4][5].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on U6 small nuclear RNA 9 (RNU6-9).